Research Library
Modified Citrus Pectin Slows Prostate Specific Antigen Doubling Time in Men with Prostate Cancer
Authors: Brad Guess, Mark Scholz, Stephen Strum, Richard Lam, Henry Johnson, Robert Jennrich, Dorena Rode
Source: Proceedings of the Science of the Whole Person Healing Conference March 2003 Washington D.C.
Abstract
The purpose of this trial was to investigate the effect of the nutritional supplement, modified citrus pectin (MCP), on prostate specific antigen (PSA) levels in men with prostate cancer and after localized treatment (radical prostatectomy, radiation or cryosurgery) designed to eradicate the primary tumor. Men with biochemical relapse evidenced by increasing PSA levels were included in the study. All men had low levels of PSA (<10ng/ml). In the ten men that completed the study, PSA was monitored for a minimum of six months prior to inclusion and during a one year supplementation of 14.4 grams/day of modified citrus pectin (PectaSol®, EcoNugenics, Inc., Santa Rosa, California 95407). The rate of PSA increase slowed (p-value < .01) in seven (70%) of the ten men after taking MCP for 12 months in comparison to before taking MCP. This clinical trial suggests MCP lengthens the PSADT in men with prostate cancer and low levels of PSA.